Mauro Maniscalco
Overview
Explore the profile of Mauro Maniscalco including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
174
Citations
1378
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Maniscalco M, Candia C, Fuschillo S, Ambrosino P, Paris D, Motta A
J Breath Res
. 2024 Sep;
18(4).
PMID: 39270682
Exhaled breath condensate (EBC) is used as a promising noninvasive diagnostic tool in the field of respiratory medicine. EBC is achieved by cooling exhaled air, which contains aerosolized particles and...
12.
Stanziola A, Candia C, Nazzaro G, Caso A, Merola C, Gallotti L, et al.
Front Pharmacol
. 2024 Aug;
15:1449220.
PMID: 39175541
Background: Severe eosinophilic asthma (SEA) is often linked to a dysregulation in the Interleukin-(IL)-5 axis. Mepolizumab, a humanized monoclonal antibody, reduces eosinophils by directly binging to IL-5, potentially restoring homeostatic...
13.
Papi A, Forini G, Maniscalco M, Aliani M, Fabbri L
Eur J Intern Med
. 2024 Aug;
129:131-132.
PMID: 39117553
No abstract available.
14.
Ambrosino P, Marcuccio G, Raffio G, Formisano R, Candia C, Manzo F, et al.
Life (Basel)
. 2024 Jul;
14(7).
PMID: 39063652
Over the past 15 years, the paradigm of viewing the upper and lower airways as a unified system has progressively shifted the approach to chronic respiratory diseases (CRDs). As the...
15.
Cazzola M, Ora J, Maniscalco M, Rogliani P
Expert Rev Respir Med
. 2024 Jul;
18(7):457-468.
PMID: 39044348
Introduction: In the management of chronic obstructive pulmonary disease (COPD), inhalation therapy plays a pivotal role. However, clinicians often face the dilemma of choosing between single and multiple inhaler therapies...
16.
Papi A, Forini G, Maniscalco M, Bargagli E, Crimi C, Santus P, et al.
Eur J Intern Med
. 2024 Jul;
128:104-111.
PMID: 38981765
Introduction: Patients with chronic obstructive pulmonary disease (COPD) frequently have cardiovascular comorbidities, increasing the risk of hospitalised COPD exacerbations (H-ECOPDs) or death. This pragmatic study examined the effects of adding...
17.
DAnna S, Vitale A, DAmico G, Caruso Bavisotto C, Ambrosino P, Cappello F, et al.
Biology (Basel)
. 2024 Jun;
13(6).
PMID: 38927239
As reported by the World Health Organization (WHO), about 10-20% of people have experienced mid- to long-term effects following SARS-CoV-2 infection, collectively referred to as post-COVID-19 condition or long-COVID, including...
18.
19.
Candia C, Ambrosino P, DAnna S, Motta A, Maniscalco M
Biomark Med
. 2024 Apr;
18(8):357-361.
PMID: 38623926
Two recent articles by the same research group documented that patients with severe eosinophilic asthma exhibit an increased proportion of a subtype of eosinophils, namely CD62L inflammatory eosinophils (iEos) and...
20.
Sanduzzi Zamparelli S, Lombardi C, Candia C, Iovine P, Rea G, Vitacca M, et al.
J Clin Med
. 2024 Apr;
13(7).
PMID: 38610791
Idiopathic pulmonary fibrosis (IPF) is a chronic and irreversible fibrotic disease whose natural history is characterised by a progressive worsening of the pulmonary function, exertional dyspnoea, exercise intolerance, reduced physical...